April 28, 2023 8:32am
Means an old-fashioned way of asking what's happening after another barely there Thursday aftermarket
Pre-open indications: watch out below, I am concerned whether the upside has “legs”?
A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
Even I had computer/systems problems
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday …
Dow futures are DOWN -0.33% or (-111 points), S&P futures are DOWN -0.34% or (-13 point) and NASDAQ futures are DOWN -0.34% or (-44 points) early in the pre-open – so far
U.S. stock futures are falling Friday,
European stock markets came off session lows but remained downbeat,
Asia-Pacific markets largely rose.
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes jumped on Thursday as the Dow closed UP +524.79 points (+1.58%), the S&P closed UP +79.46 points (+1.96%) while the Nasdaq closed UP +287.99 points (+2.43%)
Economic Data Docket: The Commerce Department will release the PCE price index for March at 8:30 a.m. ET. The PCE and core PCE are the Fed's favorite inflation gauges, but Thursday's Q1 GDP report gave some strong signals about what that will be.
Thursday’s (4/27) … RegMed Investors’ (RMi) closing bell: “the market moved up, the cell and gene therapy sector traveled with it.” … https://www.regmedinvestors.com/articles/12935
Ebb and flow:
Q2/23 – 1 holiday, 7 positive close and 11 negative closes
Q1/23 –
· March – ended with 10 positive and 13 negative closes
· February – 1 holiday, 2 vacation, 7 negative and 8 positive closes
· January – 2 holidays, 11 positive and 9 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
I am ABSTAINING from any FORECAST on Friday – It’s too cloudy in this fog of market forces, macroeconomics and political “machinations” <that are just below the surface of these past and upcoming sessions>.
The BOTTOM LINE: I try to keep it simple and short!
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
I was extremely tentative about the performance of our universe as we awaited the first showing (Sangamo Therapeutics (SGMO) of earnings season – and NOTHING came out as MY prejudice shows to those who NEGLECT shareholders.
Sector market breadth remains a concern as next week earnings start rolling out …
Reiterating, “More frequently right than consequentially wrong … “The rubber is hitting the road, so those companies have to do quite well to justify it.” What is the “it” – upside as LPS (loss-per-share) numbers facilitate downslides.”
Investors should be hesitant to add to positions re concerns of electronic trading i.e., algorithms seem to be the only ones leading any upside – go with flow.
Reiterating, “A SUSTAINABLE uptrend is needed to get credibility BACK into the sector’s investment”
I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!
At ANY time, NEXT week, be ready to take partial profits and exit losers.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
